News Flash: 19 Analysts Think Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Earnings Are Under Threat

The latest analyst coverage could presage a bad day for Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.

Following the downgrade, the latest consensus from Hangzhou Tigermed Consulting's 19 analysts is for revenues of CN¥7.1b in 2025, which would reflect a credible 7.5% improvement in sales compared to the last 12 months. Statutory earnings per share are presumed to leap 175% to CN¥1.31. Prior to this update, the analysts had been forecasting revenues of CN¥8.2b and earnings per share (EPS) of CN¥2.05 in 2025. Indeed, we can see that the analysts are a lot more bearish about Hangzhou Tigermed Consulting's prospects, administering a measurable cut to revenue estimates and slashing their EPS estimates to boot.

Check out our latest analysis for Hangzhou Tigermed Consulting

Analysts made no major changes to their price target of CN¥58.79, suggesting the downgrades are not expected to have a long-term impact on Hangzhou Tigermed Consulting's valuation.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Hangzhou Tigermed Consulting's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Hangzhou Tigermed Consulting's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 7.5% growth on an annualised basis. This is compared to a historical growth rate of 20% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 13% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Hangzhou Tigermed Consulting.

The Bottom Line

The biggest issue in the new estimates is that analysts have reduced their earnings per share estimates, suggesting business headwinds lay ahead for Hangzhou Tigermed Consulting. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Hangzhou Tigermed Consulting's revenues are expected to grow slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Hangzhou Tigermed Consulting after the downgrade.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Hangzhou Tigermed Consulting going out to 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.